Mga Batayang Estadistika
| LEI | 549300H36NUI4L6U8F17 |
| CIK | 1636651 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ovid Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 13, 2025 |
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results •Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 •$7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset •OV4071, th |
|
| July 10, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 25, 2025 |
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties Exhibit 99.1 Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs NEW YORK, U.S. and STOCKHOLM, Sweden, June 25, 2025 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditi |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 13, 2025 |
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results •Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 •Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001- |
|
| March 11, 2025 |
1. OVID THERAPEUTICS INC. AMENDED AND RESTATED INSIDER TRADING POLICY I. INTRODUCTION During the course of your employment, directorship or consultancy with OVID THERAPEUTICS INC. (the “Company”), you may receive important information that is not yet publicly available (“inside information”) about the Company or about other publicly traded companies with which the Company has business dealings. Be |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 11, 2025 |
Amended Non-Employee Director Compensation Policy, effective February 22, 2024 315801271 v1 1 OVID THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY This amended Non-Employee Director Compensation Policy, effective February 22, 2024 (this “Policy”), supersedes and replaces that certain Non-Employee Director Compensation Policy dated May 5, 2022, as amended from time to time. Each member of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 Ovid Therapeut |
|
| March 11, 2025 |
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results •Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic •Topline results from Phase 1 study of O |
|
| March 11, 2025 |
Form of Restricted Stock Unit Grant Notice and Award Agreement under the 2017 Equity Incentive Plan 315411651 v2 OVID THERAPEUTICS INC. RESTRICTED STOCK UNIT GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) Ovid Therapeutics Inc. (the “Company”), pursuant to its 2017 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of |
|
| March 11, 2025 |
mended Non-Employee Director Compensati 315448084 v2 1 OVID THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY This amended Non-Employee Director Compensation Policy, effective February 20, 2025 (this “Policy”), supersedes and replaces that certain Non-Employee Director Compensation Policy dated February 22, 2024, as amended from time to time. Each member of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “C |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 13, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga507422ovid11142024.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 OVID Therapeutics Inc. (Name of Issuer) Common Stock, par value $0 |
|
| November 14, 2024 |
OVID / Ovid Therapeutics Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 ovid13ga3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 12, 2024 |
, between Ovid Therapeutics Inc. and Thomas Perone. Confidential Ovid Form—NOT OPEN FOR EXECUTION PRIOR TO LEGAL REVIEW - 1 - CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (the "Agreement") is made by and between Ovid Therapeutics Inc. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| November 12, 2024 |
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results •A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs •Regulatory application for a Phase 1 trial of OV350, the first candidate fro |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 11, 2024 |
Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Margaret Alexander (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Strategy & Corporate Affairs Officer pursuant to the terms of an Executive Employment Agreement with the Company effective February 23, 2023 (the “Prior Agreement”). Executive and the Company hereby agree to this amended agre |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 13, 2024 |
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results •Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and execution •Expanded Scientific Advisory Board under the leadership of Dr. Robert Langer, adding top neurologists and neuroscientists to drive pipeline advancements •Reduced w |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 1, 2024 |
Exhibit 99.1 Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations •The Phase 1 study for OV888/GV101 capsule met its objective demonstrating a favorable safety and tolerability profile with no serious adverse events •Secondary endpoint results indicate that |
|
| June 28, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 17, 2024 |
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat Exhibit 99.1 Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat • Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints all with p-values ≤ 0.008 • Takeda’s Skyway study in Lennox |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2024 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 14, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 14, 2024 |
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results •Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal year •A Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline safety data ar |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 14, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 Ovid Therapeutics Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2017 Equity Incentive Plan Common Stock, par value $0.001 per share Rule 457(c) and 457(h) 3,534,599 (2) $3.03(3) $10,709,86 |
|
| May 14, 2024 |
140930084 v6 OVID THERAPEUTICS INC. RESTRICTED STOCK UNIT GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) Ovid Therapeutics Inc. (the “Company”), pursuant to its 2017 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 14, 2024 |
License Agreement by and between Northwestern University and the Company, dated December 15, 2016 1 Exhibit 4.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL LICENSE AGREEMENT This License Agreement (“Agreement”) made this 15th day of December, 2016 (the “Effective Date”) by and between Northwestern University, an Illinois corporation hav |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 Ovid Therapeut |
|
| March 8, 2024 |
Description of the Securities of Ovid Therapeutics Inc. Exhibit 4.2 DESCRIPTION OF THE SECURITIES OF OVID THERAPEUTICS INC. The following description of our capital stock and provisions of our amended and restated certificate of incorporation, as amended, and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation, as amended, and the amended and restated bylaws, which are included as an |
|
| March 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 8, 2024 |
2023, by and between the Company and Ligand P Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL PURCHASE AND SALE AGREEMENT dated as of October 17, 2023 between OVID THERAPEUTICS INC. and LIGAND PHARMACEUTICALS INCORPORATED i Table of Contents Page ARTICLE I DEFINED TERMS AND R |
|
| March 8, 2024 |
Amended Non-Employee Director Compensation Policy, effective May 5, 2022. 1 OVID THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY This amended Non-Employee Director Compensation Policy, effective May 5, 2022 (this “Policy”), supersedes and replaces that certain Non-Employee Director Compensation Policy dated July 24, 2015, as amended from time to time. Each member of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) who is not als |
|
| March 8, 2024 |
OVID THERAPEUTICS INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Ovid Therapeutics Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) |
|
| March 8, 2024 |
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results •Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024 •OV888 (GV101) is progressing on-track in a Phase 1, double-blind, mu |
|
| February 14, 2024 |
OVID / Ovid Therapeutics Inc. / Madison Avenue Partners, LP Passive Investment #SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Ovid Therapeutics Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2023 (Date o |
|
| February 14, 2024 |
OVID / Ovid Therapeutics Inc. / LEVIN JEREMY M - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2024 |
OVID / Ovid Therapeutics Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d14sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ovid Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the app |
|
| January 29, 2024 |
OVID / Ovid Therapeutics Inc. / BlackRock Inc. Passive Investment us6904691010012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Ovid Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 690469101 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275307 PROSPECTUS $75,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, dated November 12, 2020, or the sales agreement, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement and as of the date of this pro |
|
| November 13, 2023 |
OVID THERAPEUTICS INC. 441 9th Ave 14th Floor New York, NY 10001 OVID THERAPEUTICS INC. 441 9th Ave 14th Floor New York, NY 10001 November 13, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-275307) Request for Acceleration of Effective Date Mr. Buchmiller: In accordance with Rule 461 u |
|
| November 3, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and e |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 3, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and e |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ovid Therapeutics Inc. |
|
| November 3, 2023 |
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates Exhibit 99.1 Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates •Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat •The Company extended its expected cash runway into 2026 •Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and |
|
| November 3, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.4 OVID THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sec |
|
| November 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing un |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 18, 2023 |
Exhibit 99.1 Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 • Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid • Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway i |
|
| October 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 02, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 2, 2023 |
OVID R&D DAY OCTOBER 2, 2023 Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman Forward looking statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline and achievement of expected near |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 4, 2023 |
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates EX-99.1 2 ovid2023q2exhibit991.htm EX-99.1 Exhibit 99.1 Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates •Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor •Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 i |
|
| July 31, 2023 |
OVID / Ovid Therapeutics Inc / Madison Avenue Partners, LP Passive Investment #SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Ovid Therapeutics Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) July 20, 2023 (Date of Eve |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 5, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 Ovid Therapeutics Inc. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2023 |
Power of Attorney (included on the signature page to this Registration Statement). As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| May 5, 2023 |
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates Exhibit 99.1 Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates •Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases •Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presented by Takeda at the American Academy of Neurology meeting •OV329 Phase 1 trial contin |
|
| May 1, 2023 |
Exhibit 99.1 Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors • Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases • Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs • |
|
| May 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 27, 2023 |
Exhibit 99.1 Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting • Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studies • Sustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet pa |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Ovid Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38 |
|
| March 13, 2023 |
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results •OV329 Phase 1 trial is progressing on track •An IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator portfolio •Takeda's guidance on soticlestat remains unchanged; anticipates regulatory filings |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 OVID Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) D |
|
| February 14, 2023 |
OVID / Ovid Therapeutics Inc / LEVIN JEREMY M - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 levin-sc13ga123122.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of This Stat |
|
| February 13, 2023 |
OVID / Ovid Therapeutics Inc / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 ovid13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 10, 2023 |
OVID / Ovid Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 10, 2023 |
OVID / Ovid Therapeutics Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ovid Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| February 9, 2023 |
OVID / Ovid Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Ovid therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 690469101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 3, 2023 |
EX-99.2 3 exhibit992dayone.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Day One Biopharmaceuticals, Inc. and further agree to the filing of this agreement |
|
| February 3, 2023 |
EX-99.1 2 exhibit991dayone.htm EX-99.1 Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of zero shares of Common Stock held by Takeda Ventures, Inc., a wholly owned indirect subsidiary of Takeda Pharmaceutical Company Limited |
|
| February 3, 2023 |
EX-99.1 2 exhibit991ovid.htm EX-99.1 Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of 1,781,996 shares of the Issuer’s Common Stock that it holds directly, 5,750,000 shares of the Issuer’s Common Stock held by Takeda Pharm |
|
| February 3, 2023 |
EX-99.2 3 exhibit992ovid.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Ovid Therapeutics Inc. and further agree to the filing of this agreement as an Exhib |
|
| February 3, 2023 |
DAWN / Day One Biopharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment SC 13G/A 1 takeda-schedule13gamendmen.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 Exit Filing)* DAY ONE BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 23954D109 (CUSIP Number) June 21, 2022 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 3, 2023 |
OVID / Ovid Therapeutics Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment SC 13G/A 1 takedaschedule13gamendment.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OVID THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) July 1, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| November 8, 2022 |
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Exhibit 99.1 Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights ?Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase inhibitor ?The Company ended Q3 2022 with cash, cash equivalents and marketable securities of $137.9 million, |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2022 |
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Exhibit 99.1 Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights ?Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 ?Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two leading epilepsy |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Was UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2022 |
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights Exhibit 99.1 Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights ? Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022 ? Data supporting OV329 in rare and treatment-resistant epilepsies expected to be presented at the upcoming EILAT |
|
| May 10, 2022 |
Exhibit 10.1 Ovid Therapeutics Inc. Non-Employee Director Compensation Policy This amended Non-Employee Director Compensation Policy, effective May 5, 2022 (this ?Policy?), supersedes and replaces that certain Non-Employee Director Compensation Policy dated July 24, 2015, as amended from time to time. Each member of the Board of Directors (the ?Board?) of Ovid Therapeutics Inc. (the ?Company?) who |
|
| May 10, 2022 | ||
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 2, 2022 |
DEFA14A 1 ovidproxynoticeacces.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 29, 2022 |
DEF 14A 1 ovidproxy2022.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe |
|
| March 16, 2022 |
As filed with the Securities and Exchange Commission on March 16, 2022 S-8 POS 1 d300314ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. 333-263562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ovid Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 46-5270 |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Was UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 Ovid Therapeut |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 15, 2022 |
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results ? Ovid executing on its strategy to build a leading epilepsy pipeline ? OV329 expected to enter the clinic in 2022 ? Organization reshaped to reduce personnel by 20% and increase operational efficiency ? Targeted business development continues to support the pipeline NEW YORK, March 15, 2022 |
|
| March 15, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 Ovid Therapeutics Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2017 Equity Incentive Plan Common Stock, par value $0.001 per share Other 1,000,000(2) $3.34(3) $3,335,000(3) $0.0000927 $310 Tot |
|
| February 14, 2022 |
OVID / Ovid Therapeutics Inc / LEVIN JEREMY M - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 levin-sc13ga123121.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3) Under the Securities Exchange Act of 1934 OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of This Statem |
|
| February 14, 2022 |
OVID / Ovid Therapeutics Inc / During Matthew - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
OVID / Ovid Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2022 |
OVID / Ovid Therapeutics Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
OVID / Ovid Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ovid therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 690469101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| January 3, 2022 |
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators EX-99.1 3 ovid-ex9917.htm EX-99.1 Exhibit 99.1 Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators • Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies • Collaboration with Dr. Stephen Moss, founder of Tufts Laboratory for Basic and Translational Neuroscience Resear |
|
| January 3, 2022 |
Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2021 |
Exhibit 10.1 Ovid Therapeutics Inc. Non-Employee Director Compensation Policy This amended Non-Employee Director Compensation Policy effective May 6, 2021 (this ?Policy?) supersedes and replaces that certain Non-Employee Director Compensation Policy dated July 24, 2015, and as amended on July 11, 2016, February 2, 2017, and November 13, 2019. Each member of the Board of Directors (the ?Board?) of |
|
| November 10, 2021 |
Exhibit 99.1 Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results ? Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicines ? A development program for soticlestat, which Ovid licensed to Takeda, has begun enrolli |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 18, 2021 |
Ovid Therapeutics Corporate Overview August 2021 AUGUST 2021 ?2021 OVID THERAPEUTICS INC. |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 16, 2021 |
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights Exhibit 99.1 Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights ? Company ends Q2 ?21 with cash and cash equivalents of $212.2 million ? Recent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programs ? Ovid is actively pursuing business development opportunities to complement its neuroscience pipeline NEW Y |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 16, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Jeff Rona (?Executive?) is currently employed by OVID THERAPEUTICS INC. (the ?Company?) as its Chief Business Officer pursuant to the terms of an Executive Employment Agreement with the Company effective September 30, 2020 (the ?Prior Agreement?). Executive and the Company hereby agree to this amended agreement. The terms and conditi |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 11, 2021 |
8-K/A 1 ovid-8ka20210811.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State |
|
| July 8, 2021 |
Was UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2021 |
Ovid Therapeutics Corporate Overview June 2021 ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 June 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?will,? ?believe,? |
|
| June 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2021 |
Ovid Therapeutics Corporate Overview May 2021 ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 May 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?will,? ?believe,? ?e |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 13, 2021 |
Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| May 13, 2021 |
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update ? Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sales if soticles |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 30, 2021 |
DEF 14A 1 ovid-def14a20210610.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 30, 2021 |
DEFA14A 1 ovid-defa14a20210430.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) April 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 19, 2021 |
Ovid Therapeutics Corporate Overview April 19, 2021 ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 April 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?will,? ?beli |
|
| April 19, 2021 |
Exhibit 99.1 OVID Provides Update on OV101 Program and the Prioritization of its Resources Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID?s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly Operating Expenses Guidance of Between $8 Million and $10 Million Beginning in 2Q 2021 NEW YORK, April 19, 2021 - Ov |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 OVID Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 690469101 (CUSIP Number) April 13, 2 |
|
| April 9, 2021 |
Ovid Therapeutics Corporate Overview April 2021 ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 April 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements ?2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?may,? ?will,? ?believe, |
|
| April 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 1, 2021 |
Termination of a Material Definitive Agreement 8-K 1 ovid-8k20210401.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction o |
|
| March 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 30, 2021 |
News Release Exhibit 99.1 Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat New York, March 30, 2021 ?Ovid Therapeutics Inc. (NASDAQ: OVID) (?Ovid?), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the closing of the Royalty, Licen |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 17, 2021 Registration No. |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 Ovid Therapeut |
|
| March 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 ovid-8k20210315.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction o |
|
| March 15, 2021 |
EX-10.18 3 ovid-ex1018728.htm EX-10.18 Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 21st day of October, 2019, between Jason Tardio (“Executive”) and OVID THERAPEUTICS INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 6. WHEREAS, the Company is a biopharmaceutical company; W |
|
| March 15, 2021 |
Exhibit 10.19 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Thomas Perone (?Executive?) is currently employed by OVID THERAPEUTICS INC. (the ?Company?) as its General Counsel, Corporate Secretary and Chief Compliance Officer pursuant to the terms of an Executive Employment Agreement with the Company effective March 11, 2019 (the ?Prior Agreement?). Executive and the Company hereby agree to t |
|
| March 15, 2021 |
Exhibit 99.1 Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 • Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing • |
|
| March 15, 2021 |
Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of the 30th day of September, 2020, between Jeff Rona (?Executive?) and OVID THERAPEUTICS INC. (the ?Company?). Certain capitalized terms used in this Agreement are defined in Section 6. WHEREAS, the Company is a biopharmaceutical company; WHEREAS, the Company desires to employ Ex |
|
| March 15, 2021 |
Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) March 4, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| March 9, 2021 |
SC 13G 1 ovidthera13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Ovid Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) March 4, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| March 3, 2021 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 3, 2021 |
Ovid Therapeutics Corporate Overview March 3, 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 March 2021 Exhibit 99.1 Disclaimers and Forward-Looking Statements ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect, |
|
| March 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OVID THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OVID THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) OVID THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE (Title of Class of Securities) 690469101 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 OVID Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 690469101 (CUSIP Number) December 31 |
|
| December 21, 2020 |
8-K 1 ovid-8k20201221.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdictio |
|
| December 1, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 1, 2020 |
Exhibit 99.1 Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint • OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA • Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome expected to begin in the First Half of 2021 NEW YORK |
|
| November 20, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250054 PROSPECTUS $75,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having |
|
| November 18, 2020 |
CORRESP OVID THERAPEUTICS INC. 1460 Broadway, Suite 15044 New York, NY 10036 November 18, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada Sarmento Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-250054) Request for Acceleration of Effective Date Ms. Sarmento: In accordance with Ru |
|
| November 13, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2020 Registration No. |
|
| November 13, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized an |
|
| November 13, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existin |
|
| November 13, 2020 |
Sales Agreement dated as of November 12, 2020, between the Registrant and Cowen and Company, LLC. EX-1.2 Exhibit 1.2 OVID THERAPEUTICS INC. Common Stock (par value $0.001 per share) SALES AGREEMENT November 12, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Ovid Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Placement Shares |
|
| November 13, 2020 |
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| November 13, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 OVID THERAPEUTICS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OVID THERAPEUTICS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between OVID THERAPEUTICS INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized an |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| November 13, 2020 |
Form of Indenture, between the Registrant and one or more trustees to be named. EX-4.5 Exhibit 4.5 OVID THERAPEUTICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 12, 2020 |
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update • On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 • Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome aft |
|
| October 22, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 22, 2020 |
Angelman Syndrome & OV101 (gaboxadol) Seminar October 22, 2020 October 22, 2020 ©2020 OVID THERAPEUTICS INC. |
|
| September 30, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 30, 2020 |
Exhibit 99.1 Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies • Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time • In CDD patients, median motor |
|
| August 26, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 OVID THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 26, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.: 333-225391 PROSPECTUS SUPPLEMENT (To Prospectus dated June 19, 2018) 6,250,000 Shares Common Stock We are offering 6,250,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “OVID.” On August 24, 2020, the last reported sale price of our common stock was $6.37 per sh |
|
| August 26, 2020 |
EX-1.1 Exhibit 1.1 6,250,000 Shares Ovid Therapeutics Inc. Common Stock UNDERWRITING AGREEMENT August 25, 2020 COWEN AND COMPANY, LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Dear Sirs: 1. INTRODUCTORY. Ovi |
|
| August 26, 2020 |
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock EX-99.1 Exhibit 99.1 Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock NEW YORK, August 25, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of an underwritten offering (the “Offering”) of 6,250,000 s |
|
| August 25, 2020 |
Phase 2 ELEKTRA Trial Positive Topline Results August 25, 2020 ©2020 OVID THERAPEUTICS INC. |
|
| August 25, 2020 |
Exhibit 99.1 News Release Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome − Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome study populat |
|
| August 25, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2020 |
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update • Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020 • Multiple data readouts for soticlestat expected in Q3 2020, including from the randomized Phase 2 ELEKTRA trial in Dravet syndrome and Lennox-Gastau |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 13, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 19, 2020 |
Exhibit 99.1 Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome NEW YORK, June 19, 2020 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted |
|
| June 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 17, 2020 |
Jeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome June 17, 2020 OV935 (soticlestat) Educational Seminar Exhibit 99.1 Jeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics Welcome Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipat |
|
| June 17, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 5, 2020 |
8-K 1 ovid-8k20200605.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of |
|
| May 27, 2020 |
OVID / Ovid Therapeutics Inc. / Tls Advisors Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) OVID Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 690469101 (CUSIP Number) Terry Regas 71 S. Wacker Dr. Suite 1900 Chicago, IL 60606 312-264-2196 (Name, Address and Telephone Number of Person Authorized to Receive Notic |
|
| May 13, 2020 |
OVID / Ovid Therapeutics Inc. / TradeLink Holdings LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) OVID Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 690469101 (CUSIP Number) Terry Regas 71 S. Wacker Dr. Suite 1900 Chicago, IL 60606 312-264-2196 (Name, Address and Telephone Number of Person Authorized to Receive Notic |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38085 Ovid Therapeutics Inc. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2020 |
Exhibit 99.2 Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome • OV101 met the study’s primary objective of safety and tolerability • OV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X syndrome • Results support the continued development of OV101 in |
|
| May 7, 2020 |
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update • Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X syndrome • Previously reported encouraging initial results from Phase 2 ARCADE study in CDKL5 deficiency disorder and Dup15q syndrome • Two late-stage clinical readouts expe |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| March 30, 2020 |
Exhibit 99.1 Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study NEW YORK, March 30, 2020 |
|
| March 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 13, 2020 |
March 2020 Corporate Presentation (NASDAQ: OVID) Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or ci |
|
| March 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 11, 2020 |
EXHIBIT 10.15 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Amit Rakhit (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Medical and Portfolio Management Officer pursuant to the terms of an Amended and Restated Executive Employment Agreement with the Company effective May 4, 2017 (the “Prior Agreement”). Executive and the Company hereby agree |
|
| March 11, 2020 |
Exhibit 99.1 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 • Multiple clinical data readouts across Ovid’s pipeline expected in 2020 • Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medi |
|
| March 11, 2020 |
Description of the Securities of Ovid Therapeutics Inc. EXHIBIT 4.3 DESCRIPTION OF THE SECURITIES OF OVID THERAPEUTICS INC. The following description of our capital stock and provisions of our amended and restated certificate of incorporation, as amended, and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation, as amended, and the amended and restated bylaws, which are included as an |
|
| March 11, 2020 |
EXHIBIT 10.16 THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Tim Daly (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Executive Vice President, Finance, Corporate Controller and Treasurer pursuant to the terms of an Employment Agreement dated August 17th, 2015, as amended and restated on May 5, 2017, and as amended and restated on November 1, 2019 (t |
|
| March 11, 2020 |
OVID / Ovid Therapeutics Inc. 10-K - Annual Report - 10-K 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 Ovid Therapeut |
|
| March 11, 2020 |
OVID / Ovid Therapeutics Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on March 11, 2020 Registration No. |
|
| March 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 11, 2020 |
Non-Employee Director Compensation Plan EXHIBIT 10.13 Ovid Therapeutics Inc. Non-Employee Director Compensation Policy This amended Non-Employee Director Compensation Policy effective November 13, 2019 (this “Policy”) supersedes and replaces that certain Non-Employee Director Compensation Policy dated July 24, 2015 and as amended on July 11, 2016 and February 2, 2017. Each member of the Board of Directors (the “Board”) of Ovid Therapeut |
|
| March 2, 2020 |
March 2020 Corporate Presentation (NASDAQ: OVID) Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or ci |
|
| March 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38085 46-5270895 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OVID THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
